Skip to content Skip to menu

Medicines Australia congratulates Clinical Trial of the Year award winners

Wednesday, 16 May 2018

Media Release

Medicines Australia congratulates the recipients of the Clinical Trial of the Year Awards for their outstanding achievements in Australian research at the annual Clinical Trials 2018 National Tribute and Awards Ceremony.

Medicines Australia Interim CEO, Ms Elizabeth de Somer said:” Australia has a first-class clinical trials network – that is something to celebrate, and we welcome the   commitment from the Government for this to continue with Clinical trials being exempted from nominal caps as part of changes announced in the 2018 Federal Budget to the Research and Development Tax Incentive (RDTI),”

“This event – which MA and industry are proud supporters of, showcases researchers and partnerships addressing a critical need or evidence gap in the Australian healthcare system.

“I’d like to congratulate the winners of today’s awards, and I’d like to thank those who conduct this important research for their contribution and collaboration throughout the wider MTP sector.” said Ms de Somer.

Also speaking at the awards ceremony, Minister Greg Hunt MP, Minister for Health reaffirmed the Government’s commitment to the research sector with the announcement of the reappointment of Professor Anne Kelso as head of the NHMRC for the next 5 years. Medicines Australia congratulates Professor Kelso on her reappointment and looks forward to working further with her and the NHMRC on strengthening Australia as a destination of choice for clinical trials.

Minister Hunt also announced the “Helping our Health” clinical trials campaign which aims to promote clinical trials to all Australians as a way to increase awareness and recruitment in Australian clinical trials.

The winner of the 2018 Trial of the Year Award is the Australian Placental Transfusion (APT) Trial which is the largest ever randomised controlled trial of delayed placental cord-clamping for premature infants.

Also recognised at the awards ceremony was:

  • ACTA STInG Excellence in Trial Statistics Award is the N3RO Trial (pronounced “NERO”), a clinical trial of omega-3 fish oil in reducing a chronic lung disease in premature babies.
  • The finalist for the Trial of the Year Award is the TRANSFUSE Trial, an international, multicentre, randomized, double-blind trial which investigated the age of red blood cells for transfusion and outcomes in critically ill adults.
  • The finalist for both the Trial of the Year Award and ACTA STInG Excellence in Trial Statistics Award is the PRECISE Trial, a comparative study of two drugs used to treat an aggressive brain cancer, Glioblastoma Multiforme.

-END-

CONTACT:

Natalie Wimmer

0450 728 660
nwimmer@medaus.com.au

 

Top